31 Mar Wacker
Wacker Biotech is the global biologics CDMO partner for advanced nucleic acid-based therapies. We cover the full manufacturing chain, from plasmid DNA (pDNA) to the IVT of RNA to lipid nanoparticle (LNP) formulation. Via our proprietary PLASMITEC® platform, we also produce high-quality (>90% supercoiled) plasmids for DNA vaccines and viral vector gene and cell therapies. In addition to science-driven solutions, we provide guidance from concept to commercialization and flexibly serve customer needs ranging from R&D quality and scale to GMP manufacturing for clinical and commercial supply. Our five sites in Germany, the Netherlands and USA include a state-of-the-art mRNA competence center in Halle, Germany and a pDNA center of excellence in San Diego, California, USA. Complementing these sites is a dedicated R&D center in Munich, Germany with scientific experts leading groundbreaking nucleic acid research, technology innovations and collaborations. Wacker Biotech is wholly owned by Munich-based Wacker Chemie AG, a publicly traded company founded in 1914 that pioneered some of the 20th century’s leading biochemistry advances. We have 30+ years of experience developing biologics to advance human and animal health.
